Viking Therapeutics, Inc. (VKTX) has received a Strong Buy rating from Wall Street analysts, signaling growing confidence in the biopharmaceutical company’s pipeline and strategic direction. The recommendation underscores potential upside as the firm advances therapies in metabolic and liver diseases.
- VKTX received a Strong Buy rating from multiple Wall Street firms in late December 2025.
- Pipeline candidates VK2809 and VK0214 are in development for NASH and metabolic disorders.
- Analysts anticipate key clinical and regulatory milestones in early 2026.
- Company’s market cap stands at approximately $1.2 billion as of December 2025.
- Trading volume for VKTX has increased by 38% over the past 10 trading days.
- Biotech sector benchmarks have shown a 9.4% year-to-date gain, supporting sentiment for high-conviction names.
Viking Therapeutics (VKTX) has emerged as a top-rated biotech stock following a recent Strong Buy designation from multiple Wall Street firms. The rating reflects heightened optimism around the company’s clinical-stage programs, particularly VK2809 and VK0214, which are being evaluated for non-alcoholic steatohepatitis (NASH) and other metabolic conditions. Despite no new trial data release in the past quarter, the upgrade suggests analysts are positioning for upcoming milestones in 2026, including potential Phase 2 readouts and regulatory engagement.